Article

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomas

2024-01-25

Abstract excerpt

<h4>Background</h4> Despite their success treating type B cancers, Chimeric Antigen Receptor (CAR) T cells still showed limited efficacy in certain lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy but also increase safety concerns. Several strategies have been developed to regulate their secretion using minimal promoters that are controlled by chimer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ee86931f-8033-52a2-9a42-3cd5d556295a
DOI: 10.1101/2024.01.23.576842

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasDOI 10.1101/2024.01.23.576842Read

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomasSemantic proximity Read

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cellsSemantic proximity Read

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read

Preferential disruption of HLA-A/B enhances allogeneic CAR-T cell expansion and antitumor capacity in B cell malignanciesSemantic proximity Read

Engineering human Mucosal Associated Invariant T (MAIT) cells with chimeric antigen receptors for cancer immunotherapy <sup>1</sup>Semantic proximity Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

CAR-T design: Elements and their synergistic functionSemantic proximity Read

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read

Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment EfficacySemantic proximity Read

Highly potent novel multi-armoured IL13Ra2 CAR-T subverts the immunosuppressive microenvironment of GlioblastomaSemantic proximity Read

Synthetic promoters to induce immune-effectors into the tumor microenvironmentSemantic proximity Read

CAR therapy: the CD19 paradigmSemantic proximity Read